Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
3.850
-0.070 (-1.79%)
Dec 27, 2024, 4:00 PM EST - Market closed
Nutriband Revenue
Nutriband had revenue of $645.80K in the quarter ending October 31, 2024, with 50.94% growth. This brings the company's revenue in the last twelve months to $2.02M, down -3.18% year-over-year. In the fiscal year ending January 31, 2024, Nutriband had annual revenue of $2.09M with 0.27% growth.
Revenue (ttm)
$2.02M
Revenue Growth
-3.18%
P/S Ratio
18.87
Revenue / Employee
$155,521
Employees
13
Market Cap
42.76M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Neuronetics | 72.71M |
Spectral AI | 27.26M |
ImmuCell | 23.84M |
Barinthus Biotherapeutics | 14.97M |
Lucid Diagnostics | 4.19M |
Exicure | 500.00K |
NTRB News
- 17 hours ago - Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology - GlobeNewsWire
- 23 days ago - Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 - GlobeNewsWire
- 4 weeks ago - Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology - GlobeNewsWire
- 2 months ago - Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application - Accesswire
- 2 months ago - Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica - Accesswire
- 3 months ago - Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17 - Accesswire
- 3 months ago - Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology - Accesswire
- 3 months ago - Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch - Accesswire